Market Overview

Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG

Share:
Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG
Related BLUE
18 Biggest Mid-Day Losers For Wednesday
20 Stocks Moving In Wednesday's Pre-Market Session
Global Blood Therapeutics: Short-Sellers Could Be In For A Ride (Seeking Alpha)
Related CELG
8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting
Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia
S&P 500, Dow Notch All-Time Highs; Dave & Buster's Soars 19% (Investor's Business Daily)

After market close on Wednesday, bluebird bio Inc (NASDAQ: BLUE) released early data on the relapsed/refractory multiple myeloma study. Traders flocked to the stock after the good news, and the stock was up 22 percent after hours, spiking to $74.45 at market open Thursday, before leveling out at $71.40 mid day.

BTIG Still Says Buy

Following a conference call hosted Thursday morning to discuss the results, BTIG Equity Research analyst Dana Leone published a note maintaining the earlier stated Buy rating and $83 price target on the stock, while highlighting that the dataset hints at a bluebird and Celgene Corporation (NASDAQ: CELG) combo having an “X-factor” in manufacturing CAR T products.

In an earlier published note, the analyst highlights the strong efficacy and low toxicity points demonstrated by the early data with no obvious patient differences when compared with competitor data.

“As a result, we do think the know-how of Celgene manufacturing combined with the lentiviral tech transfer from BLUE may be an X factor supporting initially superior results versus the competition,” said Leone.

At time of writing, bluebird shares were trading up around 18 percent at $71.16.

Image Credit: By WitcherGeralt (Own work) [CC BY-SA 3.0], via Wikimedia Commons

Latest Ratings for BLUE

DateFirmActionFromTo
Nov 2016BMO CapitalInitiates Coverage OnMarket Perform
Oct 2016Cantor FitzgeraldDowngradesHoldSell
Sep 2016Maxim GroupMaintainsBuy

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

 

Related Articles (CELG + BLUE)

View Comments and Join the Discussion!